Adenia Partners buys majority stake in Egyptian healthcare leader Parkville Pharmaceuticals

EGYPT—Adenia Partners, a prominent private equity firm specializing in African growth opportunities, has finalized definitive agreements to acquire a majority stake in Parkville Pharmaceuticals.

The acquisition involves purchasing shares from Admaius Capital Partners, an Africa-focused private equity firm, alongside the company’s key leadership—Dr. Sherif Bassiouny, Chairman of Parkville, and Dr. Mahmoud Farrag, the company’s CEO.

While financial terms remain undisclosed, the transaction awaits customary closing conditions and regulatory approvals before completion.

Parkville stands as a leading Egyptian healthcare and pharmaceutical company with operations spanning the pharmaceutical, cosmeceutical, and nutraceutical sectors.

Since its founding in 2008, the Cairo-headquartered company has built a reputation for developing, manufacturing, and distributing innovative products across diverse categories.

The company’s extensive portfolio encompasses skincare solutions, haircare products, deodorants, wellness items, and therapeutic pharmaceutical lines.

The company has distinguished itself through an unwavering commitment to research, quality standards, and community wellbeing.

This dedication has propelled Parkville’s rapid expansion, establishing it as a dominant local champion within Egypt’s burgeoning cosmeceutical industry.

The company’s performance has consistently surpassed numerous established local and international brands, demonstrating its competitive strength in the marketplace.

Strategic growth plans

Through this partnership with Parkville’s founders and management team, Adenia Partners aims to fuel the company’s next growth phase.

The strategic focus will center on three key areas: enhancing the product portfolio, accelerating digital transformation and e-commerce capabilities, and driving expansion into regional markets across the Middle East and Africa.

This investment marks Adenia’s inaugural entry into the Egyptian market and aligns seamlessly with the firm’s broader mission of building high-performing, sustainable businesses throughout the African continent.

Leadership perspectives

Stéphane Bacquaert, Managing Partner at Adenia Partners, expressed enthusiasm about the firm’s first Egyptian acquisition.

He emphasized the tremendous potential behind Parkville’s mission to expand access to affordable, high-quality health and personal care products throughout the region.

The investment reflects Adenia’s confidence in backing one of the region’s fastest-growing businesses.

Dr. Mahmoud Farrag, Co-Founder and CEO of Parkville Pharmaceuticals, reflected on the company’s achievements over the past two years in collaboration with Admaius and the management team.

He highlighted the substantial progress and transformation that delivered strong value creation and highly positive outcomes for all stakeholders involved.

Looking forward, Dr. Farrag conveyed excitement about partnering with Adenia to broaden the product offering, strengthen digital and commercial capabilities, and pursue regional growth opportunities.

Dr. Farrag reaffirmed Parkville’s commitment to delivering excellence to customers while fostering a healthy, empowering workplace environment for employees.

The company remains focused on generating sustainable, long-term value for investors who share Parkville’s vision.

The overarching ambition involves positioning Parkville as a champion across the Middle East and Africa regions.

Heba Hakky, Principal at Adenia Partners, noted that this investment demonstrates the firm’s strong conviction in Egypt’s long-term economic fundamentals and the strength of locally built industry champions.

She expressed eagerness to collaborate closely with Parkville’s founders and management team throughout the company’s next growth phase.

Transaction advisors

Baker McKenzie provided legal counsel to Adenia Partners throughout the transaction.

Zilla Capital served as the sole financial advisor to the existing shareholders, while Matouk Bassiouny acted as their legal counsel.